Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria

Abstract

Background Stratum 2 of the Ramipril Efficacy in Nephropathy (REIN) study has already shown that in patients with chronic nephropathies and proteinuria of 3 g or more per 24 h, angiotensin-converting enzyme (ACE) inhibition reduced the rate of decline in glomerular filtration and halved the combined risk of doubling of serum creatinine or end-stage renal failure (ESRF) found in controls on placebo plus conventional antihypertensives. In REIN stratum 1, reported here, 24 h proteinuria was 1 g or more but less than 3 g per 24 h.Methods In stratum 1 of this double-blind trial 186 patients were randomised to a ramipril or a control (placebo plus conventional antihypertensive therapy) group targeted at achieving a diastolic blood pressure of less than 90 mm Hg. The primary endpoints were change in glomerular filtration rate (GFR) and time to ESRF or overt proteinuria (> or =53 g/24 h). Median follow-up was 31 months.Findings The decline in GFR per month was not significantly different (ramipril 0.26 [SE 0.05] mL per min per 1.73m2, control 0.29 [0.06]). Progression to ESRF was significantly less common in the ramipril group (9/99 vs 18/87) for a relative risk (RR) of 2.72 (95% CI 1.22-6.08); so was progression to overt proteinuria (15/99 vs 27/87, RR 2.40 [1.27-4.52]). Patients with a baseline GFR of 45 mL/min/1.73 m2 or less and proteinuria of 1.5 g/24 h or more had more rapid progression and gained the most from ramipril treatment. Proteinuria decreased by 13% in the ramipril group and increased by 15% in the controls. Cardiovascular events were similar. As expected, the rate of decline in GFR and the frequency of ESRF were much lower in stratum 1 than they had been in stratum 2.Interpretation In non-diabetic nephropathies, ACE inhibition confers renoprotection even to patients with non-nephrotic proteinuria.

Overview

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(98)10363-x

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 19 references

Cited by

See all 910

Metadata

Authors
Ruggenenti, P., Perna, A., Gherardi, G., Garini, G., Zoccali, C., Salvadori, M., Scolari, F., Schena, F. P., & Remuzzi, G.
Affiliations
  • Mario Negri Institute for Pharmacological Research (IT)
  • Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (IT)
  • Azienda Universitaria Ospedaliera Consorziale - Policlinico Bari (IT)
Corresponding author
Ruggenenti, Piero
Venue
The Lancet
Publisher
Elsevier BV
Published
1999-07
Volume
354
Issue
9176
Pages
359-364
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W2138670606
Cited by
910
References
19
Citations by year
2026: 17 · 2025: 18 · 2024: 24 · 2023: 23 · 2022: 28 · 2021: 40 · 2020: 19 · 2019: 22 · 2018: 20 · 2017: 22 · 2016: 25 · 2015: 33 · 2014: 33 · 2013: 35 · 2012: 36
FWCI
34.19
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • The Lancet (publishedVersion)
  • PubMed (publishedVersion)
Funders
European Synchrotron Radiation Facility
Topics
  • Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
  • Health Sciences › Medicine › Nephrology › Renal Diseases and Glomerulopathies
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
Keywords
ramipril, non-diabetic nephropathy, non-nephrotic proteinuria, glomerular filtration rate decline, end-stage renal disease, renal protection, antihypertensive therapy, chronic kidney disease progression, cardiovascular events, blood pressure targets, ACE inhibitors, proteinuria
MeSH terms
Adult, Aged, Angiotensin-Converting Enzyme Inhibitors, Blood Pressure, Double-Blind Method, Female, Follow-Up Studies, Glomerular Filtration Rate, Humans, Hypertension, Renal, Kidney Failure, Chronic, Male, Middle Aged, Proteinuria, Treatment Outcome, Ramipril

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. https://app.cochat.ai/papers/10.1016/s0140-6736(98)10363-x
The paper
Ruggenenti, P., Perna, A., Gherardi, G., Garini, G., Zoccali, C., Salvadori, M., Scolari, F., Schena, F. P., & Remuzzi, G. (1999). Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. The Lancet. https://doi.org/10.1016/s0140-6736(98)10363-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.